May 8, 2024- Andrew Baum, M.D., will join Pfizer as Chief Strategy and Innovation Officer, Executive Vice President. Dr. Baum will be a member of Pfizer’s Executive Leadership Team reporting to Chairman and Chief Executive Officer, Dr. Albert Bourla. Dr. Baum joins Pfizer from Citi, where he served as Head of Global Healthcare, Managing Director Equity Research.
Prior to joining Citi in 2011, Dr. Baum covered European Pharmaceuticals at Morgan Stanley for 14 years and earlier in his career was a practicing physician at the Royal National Orthopaedic Radcliffe Hospital in Oxford where he completed his residency.
At Pfizer, Dr. Baum will play a vital role in advancing Pfizer’s long-term corporate strategic plan to maximize value for patients and shareholders. He will also be responsible for the company’s portfolio analysis and prioritization functions, business development activities, strengthening partnerships with the biotech ecosystem, and the commercial evaluation of our research pipeline.
Dr. Baum will begin his role at Pfizer on June 3, 2024, succeeding Aamir Malik, who recently moved into a new role at Pfizer as Chief U.S. Commercial Officer, Executive Vice President.